CeGaT has improved the structure of its somatic tumor reports, focusing on therapy recommendations. The refined reports put greater emphasis on clinical applicability and present therapy options in a clear structure to support treatment decisions in routine oncology practice. The new reporting structure has been implemented across all CeGaT genetic tumor diagnostics services: CancerPrecision®, CancerNeo®, CancerDetect®, CancerEssential®, and CancerFusionRx®.
Focus on clinically relevant variants
The main results table has been refined to focus on therapeutic options that are clinically applicable and available for the specific tumor entity. In addition, all biologically relevant driver mutations and known resistance mutations are included, regardless of their direct link to treatment options. This more selective approach highlights clinically relevant biomarkers while providing insight into tumor biology. It supports oncologists in identifying the most promising treatment strategies that are applicable in clinical practice. Nevertheless, the new report remains comprehensive and can provide a basis for off-label therapies. A structured appendix lists all potentially relevant biomarkers and associated medications, including the corresponding approval criteria.
Clear categorization of therapy options
The appendix has been reorganized into three tables that reflect different levels of clinical applicability.
- Table 1 lists approved drugs for the patient’s tumor entity for which defined approval restrictions are met based on the detected alterations.
- Table 2 includes approved drugs for the patient’s tumor entity, where approval restrictions are not fully met based on the detected alterations.
- Table 3 lists drugs based on the detected alterations that are currently approved for other tumor entities.
This structure allows physicians to quickly distinguish between directly applicable therapies and options that may require further clinical evaluation in an off-label setting. To support this categorization, CeGaT now conducts a pre-check of selected approval restrictions where possible.
Pre-checked approval criteria
To support treatment decisions in everyday oncology care, CeGaT pre-checks selected approval criteria as part of the reporting process. These include criteria such as the presence or absence of specific biomarkers detected in the genomic analysis and age-related approval restrictions. Some drug approvals require additional molecular or clinical information that cannot be assessed during routine reporting. These aspects, therefore, still need to be evaluated by the treating physicians or within a Molecular Tumor Board.
Learn more about CeGaT’s tumor diagnostics services.
Have a look at the new sample report: